GlaxoSmithKline

TrialScope Selected by Leading Global Pharmaceutical Company to Support Clinical Trial Disclosure and Transparency

Retrieved on: 
Wednesday, June 20, 2018
Free software, Humanities, Transparency, Disclosure, GlaxoSmithKline, Culture, Health, Public sphere

With this agreement, GlaxoSmithKline will implement two of TrialScope's solutions: TrialScope Disclosure Management and TrialScope Transparency Management.

Key Points: 
  • With this agreement, GlaxoSmithKline will implement two of TrialScope's solutions: TrialScope Disclosure Management and TrialScope Transparency Management.
  • TrialScope's Disclosure Management solution centralizes, tracks and complies with clinical trial disclosure processes, mitigating compliance risks, and giving sponsors greater control over their clinical trial disclosure.
  • "We are thrilled to be working with GlaxoSmithKline to support its global trial disclosure and transparency management," said Jeff Kozloff, TrialScope CEO.
  • TrialScope simplifies the complexities of clinical trial transparency.

TrialScope Selected by Leading Global Pharmaceutical Company to Support Clinical Trial Disclosure and Transparency

Retrieved on: 
Wednesday, June 20, 2018
Free software, Humanities, Transparency, Disclosure, GlaxoSmithKline, Culture, Health, Public sphere

With this agreement, GlaxoSmithKline will implement two of TrialScope's solutions: TrialScope Disclosure Management and TrialScope Transparency Management.

Key Points: 
  • With this agreement, GlaxoSmithKline will implement two of TrialScope's solutions: TrialScope Disclosure Management and TrialScope Transparency Management.
  • TrialScope's Disclosure Management solution centralizes, tracks and complies with clinical trial disclosure processes, mitigating compliance risks, and giving sponsors greater control over their clinical trial disclosure.
  • "We are thrilled to be working with GlaxoSmithKline to support its global trial disclosure and transparency management," said Jeff Kozloff, TrialScope CEO.
  • TrialScope simplifies the complexities of clinical trial transparency.

FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms

Retrieved on: 
Tuesday, May 8, 2018
Muscarinic antagonists, Urology, Carbamates, GlaxoSmithKline, Quinuclidines, Solifenacin, Tetrahydroisoquinolines, Medicine, Chemistry, Overactive bladder, Astellas Pharma, Mirabegron

"With the FDA approval of Myrbetriq in combination with solifenacin succinate, Astellas is able to offer an additional treatment option to individuals living with symptoms of OAB."

Key Points: 
  • "With the FDA approval of Myrbetriq in combination with solifenacin succinate, Astellas is able to offer an additional treatment option to individuals living with symptoms of OAB."
  • Myrbetriq (mirabegron), a beta3 adrenergic agonist, is indicated as monotherapy or in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
  • Solifenacin succinate is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product.
  • Myrbetriq should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB, including solifenacin succinate.